Catherine Pettit

TL;DR: Novel chalcones and bis-chalcones containing boronic acid moieties inhibited the growth of the human breast cancer cell lines at low micromolar to nanomolar concentrations and exhibited more potent inhibition of colon cancer cells expressing wild-type p53 than of an isogenic cell line that was p53-null.

TL;DR: In this paper, a series of boronic-chalcone derivatives were synthesized and tested for antitumor activity against human breast cancer cell lines, and the results showed that the chalcone derivatives are more toxic to breast cancer cells compared to normal breast cells than other known chalcones.

TL;DR: The results indicate that the novel HDAC inhibitor, Scriptaid, inhibits tumor growth in vitro and in vivo and, in conjunction with AZA, acts to re-express functional ER.

TL;DR: Investigation of the effect of PP2A on regulation of ER expression in the human breast cancer cell line MCF-7 suggested a novel pathway controlling ER expression resulting from the activation ofPP2A, potentially providing a novel therapeutic target.

TL;DR: Through the use of pharmacologic inhibitors, 5-aza 2’deoxycytidine (AZA) and Trichostatin A (TSA), it is shown that alterations in both of these mechanisms results in synergistic re-expression of ER mRNA and functional protein.